Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 11
Submit an article Journal homepage
61
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Sequential occurrence of chronic myeloproliferative and lymphoproliferative neoplasms: a collaborative retrospective study by pH-negative MPN latial group

Massimo Brecciaa Department of Translational and Precision Medicine Az. Policlinico Umberto I-Sapienza University, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-1163-6162
ORCID Icon,
Luca Petriccioneb UOC Ematologia ASL Frosinone, Frosinone, Italy
,
Caterina Tatarellic Hematology, S.Andrea Hospital, Rome, Italy
,
Marianna De Murod UOC Ematologia e trapianto di CSE, Fondazione Policlinico Campus Bio-Medico, Rome, Italy
,
Malgorzata Monica Trawinskae Hematology, S. Eugenio Hospital, Rome, Italy
,
Michelina Santopietrof Haematology and Haematopoietic Stem Cells Transplant Unit, AO San Camillo-Forlanini, Rome, Italy
,
Antonio Spadeag Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy
,
Ambra Di Verolih Hematology, Belcolle Hospital, Viterbo, Italy
,
Emilia Scalzullia Department of Translational and Precision Medicine Az. Policlinico Umberto I-Sapienza University, Rome, Italy
,
Katia Paciaronii UOSD Ematologia, ASL Roma1, Rome, Italy
,
Agostino Tafuric Hematology, S.Andrea Hospital, Rome, Italy
,
Roberto Latagliatah Hematology, Belcolle Hospital, Viterbo, Italy
,
Alessandro Andrianib UOC Ematologia ASL Frosinone, Frosinone, Italy
&
Arianna Di Napolic Hematology, S.Andrea Hospital, Rome, ItalyORCID Iconhttps://orcid.org/0000-0002-3159-5380
ORCID Icon show all
Pages 2751-2753 | Received 06 May 2022, Accepted 19 Jun 2022, Published online: 25 Jun 2022

References

  • Rumi E, Passamonti F, Elena C, et al. Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. Haematologica. 2011;96(3):454–458.
  • Vannucchi AM, Masala G, Antonioli E, et al. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiol Biomarkers Prev. 2009;18(7):2068–2073.
  • Masarova L, Cherry M, Newberry KJ, et al. Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience. Leuk Lymphoma. 2016;57(1):237–239.
  • Landtblom AR, Bower H, Andersson TM, et al. Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. Leukemia. 2018;32(10):2203–2210.
  • Frederiksen H, Farkas DK, Christiansen CF, et al. Chronic myeloproliferative neoplasms and subsequent cancer risk: a Danish population-based cohort study. Blood. 2011;118(25):6515–6520.
  • Bhatia R, Deeg HJ. Treatment-related myelodysplastic syndrome: molecular characteristics and therapy. Curr Opin Hematol. 2011;18(2):77–82.
  • Laurenti L, Tarnani M, Nichele I, et al. The coexistence of chronic lymphocytic leukemia and myeloproliperative neoplasms: a retrospective multicentric GIMEMA experience. Am J Hematol. 2011;86(12):1007–1012.
  • Tabaczewski P, Nadesan S, Lim SH. Zap-70 positive chronic lymphocytic leukemia co-existing with Jak 2 V671F positive essential thrombocythemia: a common defective stem cell? Leuk Res. 2009;33(6):854–855.
  • Kremer M, Horn T, Koch I, et al. Quantitation of the JAK2V617F mutation in microdissected bone marrow trephines: equal mutational load in myeloid lineages and rare involvement of lymphoid cells. Am J Surg Pathol. 2008;32(6):928–935.
  • Kodali S, Chen C, Rathnasabapathy C, et al. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN). Leuk Res. 2009;33(12):e236–e239.
  • Musolino C, Allegra A, Penna G, et al. Absence of the V617F JAK2 mutation in the lymphoid compartment in a patient with essential thrombocythemia and B-chronic lymphocytic leukemia and in two relatives with lymphoproliferative disorders. Acta Haematol. 2009;122(1):46–49.
  • Henry L, Carillo S, Jourdan E, et al. Association of essential thrombocythemia and chronic lymphocytic leukemia: absence of the V617F JAK2 mutation in the lymphoid compartment. Am J Hematol. 2007;82(6):500–501.
  • Hussein K, Brakensiek K, Ballmaier M, et al. B-CLL developing in a patient with PV is not affected by V617F mutation of the Janus kinase 2. Eur J Haematol. 2006;77:539–541.
  • Porpaczy E, Tripolt S, Hoelbl-Kovacic A, et al. Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood. 2018;132(7):694–706.
  • Pemmaraju N, Kantarjian H, Nastoupil L, et al. Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy. Blood. 2019;133(21):2348–2351.
  • Rumi E, Zibellini S, Boveri E, et al. Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. Am J Hematol. 2019;94(7):185–188.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.